These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 26121982)

  • 41. Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism.
    Takezako T; Unal H; Karnik SS; Node K
    Pharmacol Res; 2017 Sep; 123():40-50. PubMed ID: 28648738
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling.
    Bhuiyan MA; Ishiguro M; Hossain M; Nakamura T; Ozaki M; Miura S; Nagatomo T
    Life Sci; 2009 Jul; 85(3-4):136-40. PubMed ID: 19446572
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state.
    Miura S; Kiya Y; Kanazawa T; Imaizumi S; Fujino M; Matsuo Y; Karnik SS; Saku K
    Mol Endocrinol; 2008 Jan; 22(1):139-46. PubMed ID: 17901125
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Valsartan ameliorates the constitutive adipokine expression pattern in mature adipocytes: a role for inverse agonism of the angiotensin II type 1 receptor in obesity.
    Hasan AU; Ohmori K; Hashimoto T; Kamitori K; Yamaguchi F; Ishihara Y; Ishihara N; Noma T; Tokuda M; Kohno M
    Hypertens Res; 2014 Jul; 37(7):621-8. PubMed ID: 24599011
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Divergent Spatiotemporal Interaction of Angiotensin Receptor Blocking Drugs with Angiotensin Type 1 Receptor.
    Singh KD; Unal H; Desnoyer R; Karnik SS
    J Chem Inf Model; 2018 Jan; 58(1):182-193. PubMed ID: 29195045
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structure of the Angiotensin receptor revealed by serial femtosecond crystallography.
    Zhang H; Unal H; Gati C; Han GW; Liu W; Zatsepin NA; James D; Wang D; Nelson G; Weierstall U; Sawaya MR; Xu Q; Messerschmidt M; Williams GJ; Boutet S; Yefanov OM; White TA; Wang C; Ishchenko A; Tirupula KC; Desnoyer R; Coe J; Conrad CE; Fromme P; Stevens RC; Katritch V; Karnik SS; Cherezov V
    Cell; 2015 May; 161(4):833-44. PubMed ID: 25913193
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Constitutive activity in the angiotensin II type 1 receptor: discovery and applications.
    Unal H; Karnik SS
    Adv Pharmacol; 2014; 70():155-74. PubMed ID: 24931196
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases.
    Wallukat G; Schimke I
    Semin Immunopathol; 2014 May; 36(3):351-63. PubMed ID: 24777744
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of protein dynamics in GPCR function: insights from the β2AR and rhodopsin.
    Manglik A; Kobilka B
    Curr Opin Cell Biol; 2014 Apr; 27():136-43. PubMed ID: 24534489
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reassessment of the unique mode of binding between angiotensin II type 1 receptor and their blockers.
    Miura S; Nakao N; Hanzawa H; Matsuo Y; Saku K; Karnik SS
    PLoS One; 2013; 8(11):e79914. PubMed ID: 24260317
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Are GPCRs still a source of new targets?
    Garland SL
    J Biomol Screen; 2013 Oct; 18(9):947-66. PubMed ID: 23945874
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Critical hydrogen bond formation for activation of the angiotensin II type 1 receptor.
    Cabana J; Holleran B; Beaulieu MÈ; Leduc R; Escher E; Guillemette G; Lavigne P
    J Biol Chem; 2013 Jan; 288(4):2593-604. PubMed ID: 23223579
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structure-function of the G protein-coupled receptor superfamily.
    Katritch V; Cherezov V; Stevens RC
    Annu Rev Pharmacol Toxicol; 2013; 53():531-56. PubMed ID: 23140243
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long range effect of mutations on specific conformational changes in the extracellular loop 2 of angiotensin II type 1 receptor.
    Unal H; Jagannathan R; Bhatnagar A; Tirupula K; Desnoyer R; Karnik SS
    J Biol Chem; 2013 Jan; 288(1):540-51. PubMed ID: 23139413
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanism of GPCR-directed autoantibodies in diseases.
    Unal H; Jagannathan R; Karnik SS
    Adv Exp Med Biol; 2012; 749():187-99. PubMed ID: 22695846
    [No Abstract]   [Full Text] [Related]  

  • 56. G protein-mediated stretch reception.
    Storch U; Mederos y Schnitzler M; Gudermann T
    Am J Physiol Heart Circ Physiol; 2012 Mar; 302(6):H1241-9. PubMed ID: 22227128
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis.
    Vejakama P; Thakkinstian A; Lertrattananon D; Ingsathit A; Ngarmukos C; Attia J
    Diabetologia; 2012 Mar; 55(3):566-78. PubMed ID: 22189484
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Renin-Angiotensin system modulators modestly reduce vascular risk in persons with prior stroke.
    Lee M; Saver JL; Hong KS; Hao Q; Chow J; Ovbiagele B
    Stroke; 2012 Jan; 43(1):113-9. PubMed ID: 22052520
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function.
    Khan BV
    Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):241-73. PubMed ID: 21893558
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation.
    Lebon G; Warne T; Edwards PC; Bennett K; Langmead CJ; Leslie AG; Tate CG
    Nature; 2011 May; 474(7352):521-5. PubMed ID: 21593763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.